Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 8Gastrointestinal 8Breast 6Tumor-Agnostic 2Thoracic 2Lymphoid 2Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Endocrine 1CNS 1

Conditions

Lung Neoplasms 2

Interventions

Carboplatin 1167Cisplatin 889Pemetrexed 845pembrolizumab 622Paclitaxel 608Docetaxel 539Gemcitabine 428Radiotherapy 390Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 296durvalumab 264Drug Therapy 260osimertinib 236atezolizumab 224Radiosurgery 194Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 131Ipilimumab 129130-nm albumin-bound paclitaxel 124Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
High-Intensity Interval Training × Thoracic × Clear all
NCT06026111 2026-04-14

ENHANCE

Dana-Farber Cancer Institute

Phase NA Recruiting
30 enrolled
Thoracic

Lung Neoplasms

NCT06215326 2024-03-01

PRE-EXELUCA

Guangdong Provincial People's Hospital

Phase NA Recruiting
100 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡